BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chang CC, Campoli M, Luo W, Zhao W, Zaenker KS, Ferrone S. Immunotherapy of melanoma targeting human high molecular weight melanoma-associated antigen: potential role of nonimmunological mechanisms. Ann N Y Acad Sci. 2004;1028:340-350. [PMID: 15650259 DOI: 10.1196/annals.1322.040] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Joo NE, Watanabe T, Chen C, Chekenya M, Stallcup WB, Kapila YL. NG2, a novel proapoptotic receptor, opposes integrin alpha4 to mediate anoikis through PKCalpha-dependent suppression of FAK phosphorylation. Cell Death Differ 2008;15:899-907. [PMID: 18292781 DOI: 10.1038/cdd.2008.22] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
2 Whiteside TL, Diergaarde B, Hong CS. Tumor-Derived Exosomes (TEX) and Their Role in Immuno-Oncology. Int J Mol Sci 2021;22:6234. [PMID: 34207762 DOI: 10.3390/ijms22126234] [Reference Citation Analysis]
3 Anikeeva N, Panteleev S, Mazzanti NW, Terai M, Sato T, Sykulev Y. Efficient killing of tumor cells by CAR-T cells demands engagement of a larger number of CARs as opposed to TCRs. J Biol Chem 2021;:101033. [PMID: 34371020 DOI: 10.1016/j.jbc.2021.101033] [Reference Citation Analysis]
4 de Bruyn M, Rybczynska AA, Wei Y, Schwenkert M, Fey GH, Dierckx RA, van Waarde A, Helfrich W, Bremer E. Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo. Mol Cancer 2010;9:301. [PMID: 21092273 DOI: 10.1186/1476-4598-9-301] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 4.3] [Reference Citation Analysis]
5 Wood LM, Paterson Y. Attenuated Listeria monocytogenes: a powerful and versatile vector for the future of tumor immunotherapy. Front Cell Infect Microbiol 2014;4:51. [PMID: 24860789 DOI: 10.3389/fcimb.2014.00051] [Cited by in Crossref: 70] [Cited by in F6Publishing: 61] [Article Influence: 10.0] [Reference Citation Analysis]
6 Drake AS, Brady MT, Wang XH, Sait SJ, Earp JC, Ghoshal Gupta S, Ferrone S, Wang ES, Wetzler M. Targeting 11q23 positive acute leukemia cells with high molecular weight-melanoma associated antigen-specific monoclonal antibodies. Cancer Immunol Immunother 2009;58:415-27. [PMID: 18677475 DOI: 10.1007/s00262-008-0567-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
7 Brehm H, Niesen J, Mladenov R, Stein C, Pardo A, Fey G, Helfrich W, Fischer R, Gattenlöhner S, Barth S. A CSPG4-specific immunotoxin kills rhabdomyosarcoma cells and binds to primary tumor tissues. Cancer Lett 2014;352:228-35. [PMID: 25016058 DOI: 10.1016/j.canlet.2014.07.006] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
8 Hashimoto R, Kanda M, Takami H, Shimizu D, Oya H, Hibino S, Okamura Y, Yamada S, Fujii T, Nakayama G. Aberrant expression of melanoma-associated antigen-D2 serves as a prognostic indicator of hepatocellular carcinoma outcome following curative hepatectomy. Oncol Lett. 2015;9:1201-1206. [PMID: 25663882 DOI: 10.3892/ol.2014.2823] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
9 Shimizu D, Kanda M, Sugimoto H, Sueoka S, Takami H, Ezaka K, Tanaka Y, Hashimoto R, Okamura Y, Iwata N, Tanaka C, Yamada S, Fujii T, Nakayama G, Koike M, Nomoto S, Fujiwara M, Kodera Y. NRAGE promotes the malignant phenotype of hepatocellular carcinoma. Oncol Lett 2016;11:1847-54. [PMID: 26998088 DOI: 10.3892/ol.2016.4120] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
10 Yadavilli S, Hwang EI, Packer RJ, Nazarian J. The Role of NG2 Proteoglycan in Glioma. Transl Oncol 2016;9:57-63. [PMID: 26947882 DOI: 10.1016/j.tranon.2015.12.005] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 6.4] [Reference Citation Analysis]
11 Harrer DC, Schuler G, Dörrie J, Schaft N. CSPG4-Specific CAR T Cells for High-Risk Childhood B Cell Precursor Leukemia. Int J Mol Sci 2019;20:E2764. [PMID: 31195686 DOI: 10.3390/ijms20112764] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
12 Risberg K, Fodstad Ø, Andersson Y. Synergistic anticancer effects of the 9.2.27PE immunotoxin and ABT-737 in melanoma. PLoS One 2011;6:e24012. [PMID: 21915275 DOI: 10.1371/journal.pone.0024012] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
13 Tikhmyanova N, Little JL, Golemis EA. CAS proteins in normal and pathological cell growth control. Cell Mol Life Sci 2010;67:1025-48. [PMID: 19937461 DOI: 10.1007/s00018-009-0213-1] [Cited by in Crossref: 129] [Cited by in F6Publishing: 114] [Article Influence: 10.8] [Reference Citation Analysis]
14 Benassi MS, Pazzaglia L, Chiechi A, Alberghini M, Conti A, Cattaruzza S, Wassermann B, Picci P, Perris R. NG2 expression predicts the metastasis formation in soft-tissue sarcoma patients. J Orthop Res. 2009;27:135-140. [PMID: 18634019 DOI: 10.1002/jor.20694] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.7] [Reference Citation Analysis]
15 Jordaan S, Chetty S, Mungra N, Koopmans I, van Bommel PE, Helfrich W, Barth S. CSPG4: A Target for Selective Delivery of Human Cytolytic Fusion Proteins and TRAIL. Biomedicines 2017;5:E37. [PMID: 28657611 DOI: 10.3390/biomedicines5030037] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
16 Wallecha A, Carroll KD, Maciag PC, Rivera S, Shahabi V, Paterson Y. Multiple effector mechanisms induced by recombinant Listeria monocytogenes anticancer immunotherapeutics. Adv Appl Microbiol 2009;66:1-27. [PMID: 19203646 DOI: 10.1016/S0065-2164(08)00801-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
17 Farnedi A, Rossi S, Bertani N, Gulli M, Silini EM, Mucignat MT, Poli T, Sesenna E, Lanfranco D, Montebugnoli L, Leonardi E, Marchetti C, Cocchi R, Ambrosini-Spaltro A, Foschini MP, Perris R. Proteoglycan-based diversification of disease outcome in head and neck cancer patients identifies NG2/CSPG4 and syndecan-2 as unique relapse and overall survival predicting factors. BMC Cancer 2015;15:352. [PMID: 25935541 DOI: 10.1186/s12885-015-1336-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
18 Rivera Z, Ferrone S, Wang X, Jube S, Yang H, Pass HI, Kanodia S, Gaudino G, Carbone M. CSPG4 as a target of antibody-based immunotherapy for malignant mesothelioma. Clin Cancer Res 2012;18:5352-63. [PMID: 22893632 DOI: 10.1158/1078-0432.CCR-12-0628] [Cited by in Crossref: 47] [Cited by in F6Publishing: 30] [Article Influence: 5.2] [Reference Citation Analysis]
19 Erfurt C, Müller E, Emmerling S, Klotz C, Hertl M, Schuler G, Schultz ES. Melanoma-associated chondroitin sulphate proteoglycan as a new target antigen for CD4+ T cells in melanoma patients. Int J Cancer 2009;124:2341-6. [PMID: 19173283 DOI: 10.1002/ijc.24235] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
20 Kanda M, Nomoto S, Oya H, Takami H, Shimizu D, Hibino S, Hashimoto R, Kobayashi D, Tanaka C, Yamada S. The Expression of Melanoma-Associated Antigen D2 Both in Surgically Resected and Serum Samples Serves as Clinically Relevant Biomarker of Gastric Cancer Progression. Ann Surg Oncol. 2016;23 Suppl 2:S214-S221. [PMID: 25743330 DOI: 10.1245/s10434-015-4457-8] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
21 Maciag PC, Seavey MM, Pan ZK, Ferrone S, Paterson Y. Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature. Cancer Res 2008;68:8066-75. [PMID: 18829565 DOI: 10.1158/0008-5472.CAN-08-0287] [Cited by in Crossref: 70] [Cited by in F6Publishing: 39] [Article Influence: 5.4] [Reference Citation Analysis]
22 Medic S, Pearce RL, Heenan PJ, Ziman M. Molecular markers of circulating melanoma cells. Pigment Cell Res 2007;20:80-91. [PMID: 17371435 DOI: 10.1111/j.1600-0749.2006.00356.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
23 Kanda M, Sugimoto H, Kodera Y. Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinoma. World J Gastroenterol. 2015;21:10584-10597. [PMID: 26457018 DOI: 10.3748/wjg.v21.i37.10584] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 40] [Article Influence: 7.4] [Reference Citation Analysis]
24 Misra S, Hascall VC, Atanelishvili I, Moreno Rodriguez R, Markwald RR, Ghatak S. Utilization of Glycosaminoglycans/Proteoglycans as Carriers for Targeted Therapy Delivery. Int J Cell Biol 2015;2015:537560. [PMID: 26448753 DOI: 10.1155/2015/537560] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
25 Garusi E, Rossi S, Perris R. Antithetic roles of proteoglycans in cancer. Cell Mol Life Sci 2012;69:553-79. [DOI: 10.1007/s00018-011-0816-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
26 Wang Y. Potential biomarkers for malignant melanoma. WJD 2013;2:44. [DOI: 10.5314/wjd.v2.i4.44] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
27 Barrett A, Pellet-Many C, Zachary IC, Evans IM, Frankel P. p130Cas: a key signalling node in health and disease. Cell Signal 2013;25:766-77. [PMID: 23277200 DOI: 10.1016/j.cellsig.2012.12.019] [Cited by in Crossref: 57] [Cited by in F6Publishing: 49] [Article Influence: 6.3] [Reference Citation Analysis]